Neuren Pharmaceuticals Profile

USD 0.16  7.51%

Neuren Pharmaceuticals Summary

Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in PWC Tower and employs 10 people. The company currently falls under 'Small-Cap' category with current market capitalization of 215.26 M. Neuren Pharmaceuticals Limited has 92.1 M outstanding shares. NEUREN PHARMACEUT has accumulated about 3.61 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check Neuren Pharmaceuticals Probability Of Bankruptcy

Target Price Odds Analysis

Odds Below 2.29HorizonTargetOdds Above 2.29
?%30 days 2.29 ?%
Based on normal probability distribution, the odds of Neuren Pharmaceuticals to move above current price in 30 days from now is about 0.0% (This Neuren Pharmaceuticals Limited probability density function shows the probability of Neuren Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Orleans Capital Management CorpCommon Shares10 K1000
Orleans Capital Management CorpCommon Shares10 K1000
View Neuren Pharmaceuticals Diagnostics

Key Fundamentals

Neuren Pharmaceuticals Against Markets

Current Ratings

Neuren Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Neuren Pharmaceuticals Limited are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand. Neuren Pharmaceuticals is traded on OTC Market in USA. more
NameNeuren Pharmaceuticals Limited
CEO, Managing DirectorLarry GlassView All
Macroaxis Advice
InstrumentUSA Stock View All
Business AddressPWC Tower
ExchangeOTC Market
Contact Number61 3 9092 0480
CurrencyUSD - US Dollar

Diversify with Neuren Pharmaceuticals Limited

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Neuren Pharmaceuticals Limited to your portfolio


Neuren Pharmaceuticals Corporate Executives
Jon Pilcher CFO, Company Secretary
James Shaw COO
Please see also Stocks Correlation. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.